NOX4 links to ARDS risk and progression
Official title: Experimental and Computational Investigation of NOX4-Dependent Mechanisms in ARDS Susceptibility
Funded at Marquette University · NIH-11444021 · Data updated 2026-11-12
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Marquette University NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | August 15, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $557,963 |
| NIH project number | 2R15HL129209-04 |
| Project ID | NIH-11444021 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with ARDS or at high risk for severe ARDS who are undergoing or at risk of hyperoxia exposure.
✕Less likely to help
Healthy individuals or ARDS patients not involved in hyperoxia exposure studies may not directly benefit.
What this research studies
This project explores how oxidative stress and energy production in lung cells contribute to ARDS severity, using both human data and animal models to study NOX4’s role during high oxygen exposure. Researchers will examine mitochondrial function, NOX4 activity, and how these factors affect blood vessel leakage and lung injury. The study may identify biomarkers or pathways that help predict which patients are at higher risk of severe ARDS and could benefit from targeted interventions. Results could inform ways to tailor oxygen therapy and other treatments to individual patients. The work combines laboratory experiments with analyses of clinical samples to bridge basic biology and patient care.
Why it matters
Potential benefit: If successful, the research could lead to better risk prediction and more precise therapies for patients with ARDS.
How similar studies have gone: Prior work suggests NOX4 and mitochondrial function influence lung injury, but a translational link to NOX4-driven ARDS susceptibility is being explored in this project.
Where this research is happening
-
Marquette University
Milwaukee, United States Active
Researchers
- Principal investigator: Audi, Said H — Marquette University
- Study coordinator: Audi, Said H
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
-
Innovative immune therapy with antibiotics to treat deadly inflammation in sepsis and ARDS in older adults
A new approach combines an antibiotic strategy with a special immune-based treatment to help older patients who have sepsis or ARDS from severe bacterial infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.